| Selection of resistant bacteria at very low antibiotic concentrations E Gullberg, S Cao, OG Berg, C Ilbäck, L Sandegren, D Hughes, ... PLoS pathogens 7 (7), e1002158, 2011 | 1890 | 2011 |
| In vitro activity of apramycin against multidrug-, carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii M Juhas, E Widlake, J Teo, DL Huseby, JM Tyrrell, YS Polikanov, O Ercan, ... Journal of Antimicrobial Chemotherapy 74 (4), 944-952, 2019 | 103 | 2019 |
| FimH alleles direct preferential binding of Salmonella to distinct mammalian cells or to avian cells A Guo, S Cao, L Tu, P Chen, C Zhang, A Jia, W Yang, Z Liu, H Chen, ... Microbiology 155 (5), 1623-1633, 2009 | 57 | 2009 |
| A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants DD Khan, P Lagerbäck, S Cao, U Lustig, EI Nielsen, O Cars, D Hughes, ... Journal of Antimicrobial Chemotherapy 70 (11), 3051-3060, 2015 | 56 | 2015 |
| Alternative Evolutionary Pathways for Drug-Resistant Small Colony Variant Mutants in Staphylococcus aureus S Cao, DL Huseby, G Brandis, D Hughes MBio 8 (3), 10.1128/mbio. 00358-17, 2017 | 54 | 2017 |
| Can phylogenetic type predict resistance development? H Nazir, S Cao, F Hasan, D Hughes Journal of antimicrobial chemotherapy 66 (4), 778-787, 2011 | 39 | 2011 |
| Model‐informed drug development for antimicrobials: translational PK and PK/PD modeling to predict an efficacious human dose for apramycin T Sou, J Hansen, E Liepinsh, M Backlund, O Ercan, S Grinberga, S Cao, ... Clinical Pharmacology & Therapeutics 109 (4), 1063-1073, 2021 | 37 | 2021 |
| Genetic Complexity of Fusidic Acid-Resistant Small Colony Variants (SCV) in Staphylococcus aureus J Lannergård, S Cao, T Norström, A Delgado, JE Gustafson, D Hughes PLoS One 6 (11), e28366, 2011 | 34 | 2011 |
| Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data EI Nielsen, DD Khan, S Cao, U Lustig, D Hughes, DI Andersson, ... Journal of Antimicrobial Chemotherapy 72 (11), 3108-3116, 2017 | 32 | 2017 |
| Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice K Becker, V Aranzana-Climent, S Cao, A Nilsson, R Shariatgorji, ... Clinical Microbiology and Infection 27 (9), 1315-1321, 2021 | 31 | 2021 |
| Discovery and hit-to-lead optimization of benzothiazole scaffold-based DNA gyrase inhibitors with potent activity against Acinetobacter baumannii and Pseudomonas aeruginosa AE Cotman, M Durcik, D Benedetto Tiz, F Fulgheri, D Secci, M Sterle, ... Journal of medicinal chemistry 66 (2), 1380-1425, 2023 | 28 | 2023 |
| Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination S Cao, A Guo, Z Liu, Y Tan, G Wu, C Zhang, Y Zhao, H Chen Infection and immunity 77 (10), 4679-4687, 2009 | 24 | 2009 |
| New dual inhibitors of bacterial topoisomerases with broad-spectrum antibacterial activity and in vivo efficacy against vancomycin-intermediate Staphylococcus aureus M Durcik, AE Cotman, Z Toplak, S Mozina, Z Skok, PE Szili, M Czikkely, ... Journal of medicinal chemistry 66 (6), 3968-3994, 2023 | 21 | 2023 |
| Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis K Becker, S Cao, A Nilsson, M Erlandsson, SK Hotop, J Kuka, J Hansen, ... EBioMedicine 73, 2021 | 21 | 2021 |
| Design, synthesis and in vitro biological evaluation of oligopeptides targeting E. coli type I signal peptidase (LepB) M De Rosa, L Lu, E Zamaratski, N Szałaj, S Cao, H Wadensten, ... Bioorganic & Medicinal Chemistry 25 (3), 897-911, 2017 | 19 | 2017 |
| Boronic ester-linked macrocyclic lipopeptides as serine protease inhibitors targeting Escherichia coli type I signal peptidase N Szałaj, L Lu, A Benediktsdottir, E Zamaratski, S Cao, G Olanders, ... European Journal of Medicinal Chemistry 157, 1346-1360, 2018 | 18 | 2018 |
| Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia V Aranzana-Climent, D Hughes, S Cao, M Tomczak, M Urbas, D Zabicka, ... Clinical Microbiology and Infection 28 (10), 1367-1374, 2022 | 17 | 2022 |
| Soluble expression and purification of the anthrax protective antigen in E. coli and identification of a novel dominant-negative mutant N435C G Wu, C Feng, Y Hong, A Guo, S Cao, J Dong, L Lin, Z Liu Applied microbiology and biotechnology 87, 609-616, 2010 | 17 | 2010 |
| Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors: Synthesis and biological evaluation A Benediktsdottir, L Lu, S Cao, E Zamaratski, A Karlén, SL Mowbray, ... European Journal of Medicinal Chemistry 224, 113699, 2021 | 16 | 2021 |
| A chimeric protein that functions as both an anthrax dual-target antitoxin and a trivalent vaccine G Wu, Y Hong, A Guo, C Feng, S Cao, CC Zhang, R Shi, Y Tan, Z Liu Antimicrobial agents and chemotherapy 54 (11), 4750-4757, 2010 | 16 | 2010 |
Diarmaid HughesUppsala UniversityVerified email at imbim.uu.se
